PFIZER INC

PFE
Pharmaceutical preparations
Last filing · Quarter 2 · Jun 28, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

40 more quarters with Pro

PFIZER INC back to 2009, every line as filed.

Create a free account
USD ($)
$ in Millions 		Jun 28, 2026Mar 29, 2026Sep 28, 2025Jun 29, 2025Mar 30, 2025Sep 29, 2024Jun 30, 2024Mar 31, 2024Oct 1, 2023Jul 2, 2023Apr 2, 2023Oct 2, 2022Jul 3, 2022Apr 3, 2022Oct 3, 2021Jul 4, 2021Apr 4, 2021Sep 27, 2020Jun 28, 2020Mar 29, 2020Sep 29, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jul 1, 2018Apr 1, 2018Oct 1, 2017Jul 2, 2017Apr 2, 2017Oct 2, 2016Jul 3, 2016Apr 3, 2016Sep 27, 2015Jun 28, 2015Mar 29, 2015Sep 28, 2014Jun 29, 2014Mar 30, 2014Sep 29, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jul 1, 2012Apr 1, 2012Oct 2, 2011Jul 3, 2011Apr 3, 2011Oct 3, 2010Jul 4, 2010Apr 4, 2010Sep 27, 2009Jun 28, 2009
Operating Activities
                                                    
Net income/(loss) before allocation to noncontrolling interests
$ (237)
$ 2,696
$ 3,550
$ 2,928
$ 2,973
$ 4,473
$ 48
$ 3,123
$ (2,376)
$ 2,338
$ 5,556
$ 8,623
Discontinued operations––net of tax
8
(13)
0
25
0
(8)
17
(5)
12
(2)
1
(21)
Net income from continuing operations before allocation to noncontrolling interests
(246)
2,709
3,550
2,903
2,973
4,481
31
3,128
(2,388)
2,340
5,555
8,645
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
                                                    
Depreciation and amortization
1,622
1,613
1,662
1,625
1,618
1,755
1,731
1,736
1,560
1,573
1,487
1,183
Asset write-offs and impairments
4,393
32
366
154
344
649
295
136
172
57
270
229
TCJA impact
-
-
-
-
-
-
-
-
-
-
-
-
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed
-
-
-
-
-
-
-
-
-
-
-
-
Adjustments to loss on sale of HIS net assets
-
-
-
-
-
-
-
-
-
-
-
-
Write-down of HIS net assets to fair value less estimated costs to sell
-
-
-
-
-
-
-
-
-
-
-
-
Gain associated with the transfer of certain product rights to an equity-method investment
-
-
-
-
-
-
-
-
-
-
-
-
Asset write-offs, impairments and related charges
-
-
-
-
-
-
-
-
-
-
-
-
Gain on disposal of discontinued operations
-
-
-
-
-
-
-
-
-
-
-
-
Acquisition-related in-process research and development charges
-
-
-
-
-
-
-
-
-
-
-
-
Deferred taxes
(1,320)
(12)
(765)
(272)
(663)
(482)
(783)
(441)
(113)
(873)
(598)
62
Deferred taxes from discontinued operations
-
-
-
-
-
-
-
-
-
-
-
-
Share-based compensation expense
249
272
201
203
170
274
206
220
151
148
105
135
Benefit plan contributions in excess of expense/income
(112)
(173)
(84)
(105)
(229)
(128)
(137)
(201)
(145)
(122)
(200)
(386)
Net gain from the sale of investment in ViiV
(1,870)
-
-
-
-
-
-
-
-
-
-
-
Inventory write-offs and related charges associated with COVID-19 products
-
-
-
-
-
-
-
-
5,847
-
-
-
Benefit plan contributions (in excess of)/less than expense
-
-
-
-
-
-
-
-
-
-
-
-
Other adjustments, net
(66)
(93)
(292)
(101)
40
(715)
411
(151)
(427)
(416)
99
211
Other non-cash adjustments
-
-
-
-
-
-
-
-
-
-
-
-
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,816)
(1,732)
(36)
(4,989)
(1,919)
879
(3,535)
(3,336)
(1,199)
(3,916)
(5,507)
(4,109)
Net cash provided by/(used in) operating activities from continuing operations
-
-
-
-
-
-
-
-
-
4
-
5,968
Net cash provided by/(used in) operating activities from discontinued operations
-
-
-
-
-
-
-
-
-
-
-
5
Net cash provided by/(used in) operating activities
835
2,615
4,603
(582)
2,335
6,714
(1,781)
1,090
3,456
(1,208)
1,212
5,974
Investing Activities
                                                    
Purchases of property, plant and equipment
(533)
(436)
(602)
(618)
(564)
(651)
(637)
(704)
(810)
(914)
(1,139)
(841)
Purchases of short-term investments
(2,544)
(2,569)
(4,223)
(3,262)
(2,823)
(2,703)
(457)
(797)
(9,132)
(14,341)
(6,665)
(10,764)
Proceeds from redemptions/sales of short-term investments
2,038
4,576
2,736
6,545
3,955
918
1,054
658
5,424
6,194
6,400
14,936
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
1,178
(792)
(583)
1,184
(3,852)
(889)
4,725
(1,187)
5,115
(15,882)
4,665
(7,724)
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
-
-
-
-
-
-
-
-
-
-
-
-
Proceeds from redemptions and sales of short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of long-term investments
9
(104)
(129)
48
(134)
33
(73)
(35)
(74)
(41)
(51)
(303)
Proceeds from redemptions/sales of long-term investments
84
88
359
63
82
1,229
7
305
17
48
124
220
Proceeds from sales of investment in Haleon
-
0
-
-
6,311
-
-
3,491
-
-
-
-
Acquisitions of businesses, net of cash acquired
-
-
-
-
-
-
-
-
-
(25)
0
-
Dividends received from Haleon/GSK Consumer Healthcare JV (Note 2C)
-
-
-
-
-
-
-
-
-
-
-
3,960
Acquisitions of intangible assets
-
-
-
-
-
-
-
-
-
-
-
-
Proceeds from sale of business
-
-
-
-
-
-
-
-
-
-
-
-
Proceeds from redemptions and sales of long-term investments
-
-
-
-
-
-
-
-
-
-
-
-
Other investing activities, net
(1)
22
14
(12)
300
5
(18)
0
350
(525)
(18)
(109)
Net cash provided by/(used in) investing activities from continuing operations
-
-
-
-
-
-
-
-
-
-
-
(627)
Net cash provided by/(used in) investing activities from discontinued operations
-
-
-
-
-
-
-
-
-
-
-
-
Net cash provided by/(used in) investing activities
2,106
785
(2,430)
3,951
3,274
(2,057)
4,600
1,732
888
(25,485)
3,315
(627)
Financing Activities
                                                    
Proceeds from short-term borrowings
-
-
-
-
0
2,161
4,570
1,444
-
3
11
(125)
Payments on short-term borrowings
-
0
-
(151)
(2,048)
(2,922)
(4,524)
(328)
-
-
-
(3,887)
Increase in short-term borrowings
-
-
-
-
-
-
-
-
-
-
-
-
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
64
(127)
6
(517)
(386)
(1,489)
938
(2,039)
(128)
(204)
226
491
Proceeds from issuance of long-term debt
-
-
-
3,687
-
-
-
-
-
30,831
-
-
Payments on long-term debt
(1,250)
-
-
(3,750)
0
-
(1,000)
(1,250)
(1,300)
(1,000)
(269)
-
Purchases of common stock
-
-
-
-
-
-
-
-
-
-
0
-
Cash dividends paid
(2,451)
(2,445)
(2,444)
(2,445)
(2,437)
(2,380)
(2,380)
(2,372)
(2,314)
(2,315)
(2,303)
(2,245)
Proceeds from exercise of stock options
-
-
-
-
-
-
-
-
-
-
-
-
Other financing activities, net
(27)
(284)
(38)
(21)
(356)
(6)
(63)
(386)
(37)
(140)
(436)
5
Net cash provided by/(used in) financing activities from continuing operations
-
-
-
-
-
-
-
-
-
-
-
-
Net cash provided by/(used in) financing activities
(3,663)
(2,856)
(2,477)
(3,196)
(5,227)
(4,636)
(2,459)
(4,931)
(3,779)
27,174
(2,771)
(5,761)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(4)
19
2
41
(7)
9
(18)
(28)
(32)
(5)
(2)
(72)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
(727)
563
(301)
213
375
29
343
(2,137)
535
475
1,754
(487)
Effect of exchange-rate changes on cash and cash equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Net increase/(decrease) in cash and cash equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Supplemental Cash Flow Information
                                                    
Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets
-
-
-
-
-
-
-
-
-
-
-
-
Receipt of ICU Medical common stock
-
-
-
-
-
-
-
-
-
-
-
-
Promissory note from ICU Medical
-
-
-
-
-
-
-
-
-
-
-
-
Cash paid during the period for:
                                                    
Noncash transaction exchange of subsidiary common stock for the retirement of company commercial paper
-
-
-
-
-
-
-
-
-
-
-
-
Non-cash exchange of subsidiary senior notes for the retirement of company commercial paper
-
-
-
-
-
-
-
-
-
-
-
-
Exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012
-
-
-
-
-
-
-
-
-
-
-
-
Exchange of Zoetis common stock for the retirement of Pfizer commercial paper issued in 2013
-
-
-
-
-
-
-
-
-
-
-
-
Transfer of certain product rights to an equity-method investment(c)
-
-
-
-
-
-
-
-
-
-
-
-
Sale of Zoetis (our Animal Health business) for Pfizer Common Stock
-
-
-
-
-
-
-
-
-
-
-
-
Cash paid during the period for:
                                                    
Supplemental Cash Flow Information - Cash paid during the period for:
                                                    
Income taxes
3,467
72
178
3,341
152
486
2,502
184
882
1,696
329
1,821
Cash paid for interest
-
-
-
-
-
-
-
-
-
-
-
-
Interest paid
1,248
293
275
1,130
353
280
1,138
415
332
402
419
350
Interest rate hedges
(58)
62
66
(45)
74
33
(35)
33
67
(29)
60
38
Non-cash transaction:
                                                    
Non-cash transaction:
                                                    
Right-of-use assets obtained in exchange for lease liabilities
-
-
-
-
-
-
-
-
-
-
-
$ 221